|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.99 USD | +0.01% |
|
-.--% | - |
| Market Cap | 3.32B 2.92B 2.72B 2.5B 4.68B 318B 4.8B 32.3B 12.63B 157B 12.47B 12.2B 544B | P/E 2023 |
-317x | P/E 2024 | 69.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.48B 3.06B 2.85B 2.62B 4.9B 333B 5.02B 33.82B 13.23B 165B 13.06B 12.77B 570B | EV / Sales 2023 |
1.55x | EV / Sales 2024 | 1.33x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 30/09/25 | A CEO's Playbook For Navigating Crisis And Building Trust (Video) | AQ |
| 29/07/25 | Amedisys: Q2 Earnings Snapshot | AQ |
| 29/07/25 | Amedisys : Second Quarter 2025 Earnings Release Supplemental Slides | PU |
| 29/07/25 | Amedisys Reports Second Quarter 2025 Financial Results | AQ |
| 23/04/25 | Amedisys: Q1 Earnings Snapshot | AQ |
| 1 day | +0.01% |
| 1 year | 97.66 |  | 101.02 |
| 3 years | 82.15 | | 101.02 |
| 5 years | 69.36 | | 264.1 |
| 10 years | 34.58 | | 325.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Ginn
DFI | Director of Finance/CFO | 57 | 05/10/2017 |
Keith Blanchard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Denise Bohnert
CMP | Compliance Officer | 48 | 31/12/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/08/25 | Issuer sale | Chief Financial Officer | 158,296 | 0.4833% | ||
| 14/08/25 | Issuer sale | Investor Relations Manager | 53,082 | 0.1621% | ||
| 14/08/25 | Issuer sale | Compliance Officer | 40,579 | 0.1239% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 2.24B 1.97B 1.83B 1.68B 3.15B 214B 3.23B 21.75B 8.51B 106B 8.4B 8.21B 366B | 2.35B 2.06B 1.93B 1.77B 3.31B 225B 3.39B 22.84B 8.93B 111B 8.82B 8.63B 385B |
| Net income | -9.75M -8.56M -7.99M -7.34M -13.73M -934M -14.07M -94.8M -37.07M -462M -36.6M -35.8M -1.6B | 43.23M 37.99M 35.46M 32.54M 60.92M 4.14B 62.42M 420M 164M 2.05B 162M 159M 7.08B |
| Net Debt | 361M 317M 296M 272M 508M 34.56B 521M 3.51B 1.37B 17.1B 1.35B 1.33B 59.11B | 156M 137M 128M 117M 220M 14.95B 225M 1.52B 594M 7.4B 586M 573M 25.57B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMED Stock
Select your edition
All financial news and data tailored to specific country editions
